An observational study in Surgical Site Infection, sponsored by Aesculap AG. Recruiting at 11 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Aesculap AG (part of B. Braun) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Surgical Wound Infection with a site in Italy — 3 open to participants now, 3 under way, none of them phase 3. Surgical Wound Infection · Italy.
Among the 20 studies in Surgical Wound Infection with a site in Italy, this one is the only one that started in 2023, is one of 7 observational ones, and was the 17th registered.
747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.
Browse Surgical Wound Infection studies →3 of the 20 studies in Surgical Wound Infection with a site in Italy are open now. Recruiting first, the newest first:
IRCCS Policlinico S. Donato · Sites in Italy
Ages 18+
Marco Catarci · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 85 Surgical Wound Infection studies recruiting now, 62 (73%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 2,998 is above the median of 239 across 135 observational studies indexed under Surgical Wound Infection.
Median enrollment 196 across the 13 interventional studies, 2,998 across the 7 observational. Of the 12 that completed or were terminated, 2 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Aesculap AG, one of the names counted as B. Braun. Under that name alone:
Aesculap AG is the lead sponsor of 105 studies on the registry; 20 are open to participants now.
B. Braun has 2 studies filed under Surgical Wound Infection — fewer than ten, so there is no comparison to draw.
1 of the studies in Surgical Wound Infection with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07275307IRCCS Policlinico S. DonatoImpact of Prontosan Wound Gel X on Surgical Site Infections in Cardiac Surgery | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies in Surgical Wound Infection with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of the study is to elucidate, if the colonization of bacteria is lower on the Novosyn® CHD suture compared to uncoated Polyglactin 910 suture, which will be assessed by the incidence of surgical site infections (SSI: A1 and A2). The results of this registry will generate further clinical evidence for the use and the benefit of a Chlorhexidine coated suture used to close the wound after an emergency or elective laparoscopic or laparotomy surgery. The benefit for individual patients lies in the early diagnosis of complications and in the optimized postoperative controls of a clinical study.
Patients undergoing wound closure after emergency or elective laparoscopic or laparotomy surgery
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sutures will be used to close the laparotomy or trocar incision in emergency or elective surgery. The suture material will be applied for fascia closure (and subcutaneous closure if applicable) in the context of daily clinical routine
Device: Novosyn® in emergency or elective laparotomy or laparoscopic surgery
Sutures will be used to close the laparotomy or trocar incision in emergency or elective surgery. The suture material will be applied for fascia closure (and subcutaneous closure if applicable) in the context of daily clinical routine
Device: Polyglactin 910 in emergency or elective laparotomy or laparoscopic surgery
Fascia closure (and subcutaneous closure if applicable) after emergency or elective laparotomy or laparoscopic surgery.
Fascia closure (and subcutaneous closure if applicable) after emergency or elective laparotomy or laparoscopic surgery.
Frequency of surgical site infection (superficial (A1) and deep (A2)
The aim of the study is to elucidate, if the colonization of bacteria is lower on the Novosyn® CHD suture compared to uncoated Polyglactin 910 suture, which will be assessed by the incidence of surgical site infections (SSI: A1 and A2).
Time frame: until 30 days + 5 days after surgery.
Handling of the suture material
Assessment of the handling of the suture material intraoperatively using a questionnaire including different dimensions (knot security, tensile strength, knot run down, tissue drag etc.) with 5 evaluations levels (excellent, very good, good, satisfied, poor).
Time frame: intraoperatively
Length of hospital stay
Number of days the patient has to stay in hospital after emergency or elective laparotomy or laparoscopic surgery
Time frame: until discharge (approximately 10 days after surgery)
Time to return to work
Number of days the patient needed to return to work after emergency or elective laparotomy or laparoscopic surgery
Time frame: until 30 days + 5 days after surgery.
Incidence of Surgical Site Infection (SSI)
Incidence of Surgical Site Infection (SSI) (superficial (A1), deep (A2) and organ space (A3)) at the time of discharge
Time frame: at discharge (approximately 10 days after surgery)
Incidence of SSI (superficial (A1), deep (A2) and organ space (A3)) stratified by wound class
Incidence of SSI (superficial (A1), deep (A2) and organ space (A3)) stratified by wound class (Class I clean, Class II clean/contaminated, Class III contaminated, Class IV dirty/infected)
Time frame: until 30 days + 5 days after surgery
Cumulative Rate of postoperative complications
Number of postoperative complications of any kind for descriptive analysis
Time frame: discharge (approximately 10 days after surgery) and 30 days+ 5 days after surgery.
Cumulative Rate of reoperation
Number of reoperation of any kind for descriptive analysis
Time frame: at discharge (approximately 10 days after surgery) and 30 days + 5 days after surgery.
Cumulative Rate of suture removal due to wound problems
Rate of suture removal due to wound problems (infection, dehiscence, residual material requiring removal) for descriptive analysis
Time frame: at discharge (approximately 10 days after surgery) and 30 days + 5 days after surgery.
Cumulative Rate of Re-suturing
Rate of Re-suturing of any kind for descriptive analysis
Time frame: at discharge (approximately 10 days after surgery) and 30 days + 5 days after surgery.
Hernia rate
Number of Wound Hernia including umbilical hernia verified by ultra-sound examination
Time frame: 30 days + 5 days postoperatively
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2023 (actual). Primary completion is estimated for Aug 2028, 59 months after the start.
Of 68 observational studies under Surgical Wound Infection, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 53. This study's planned 59 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.